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Comparative studies of TIMP-1 immunohistochemistry, TIMP-1 
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per cell ranging from 1 to 5 and the TIMP-1/CEN-X ratio 
ranging between 0.7 and 1.09, suggesting neither amplifica-
tion nor loss of the TIMP-1 gene. The TIMP-1 protein lev-
els measured in plasma were not significantly higher than 
TIMP-1 levels measured in healthy subjects. No correla-
tion was identified between TIMP-1 tumor cell immunore-
activities and the TIMP-1gene copy numbers or the plasma 
TIMP-1 levels. In conclusion, high immunohistochemical 
TIMP-1 protein levels in glioblastomas were not caused by 
TIMP-1 gene amplification and TIMP-1 in plasma was low 
and not directly related to tumor TIMP-1 immunoreactivity. 
The study suggests that TIMP-1 immunohistochemistry is 
the method of choice for future clinical studies evaluating 
TIMP-1 as a biomarker in glioblastomas.
Keywords Glioblastoma · Glioma · TIMP-1 ·  
Fluorescence in situ hybridization · Plasma ·
Immunohistochemistry
Introduction
The current standard treatment of the highly malignant 
a d mo t frequent brain tumor, the glioblastoma, includes 
surgery, radiotherapy and chemotherapy. However, glio-
blastomas remain highly treatment-resistant and thereby 
incurable [1]. In the last decade, the median overall sur-
vival has ncreased to 14.6 months and the 2-year survival 
has increased from 10.9 to 27.2%, mainly due to the intro-
duction of temozolomide [2]. This improved survival has 
increas d he interest in prognostic and predictive biomark-
ers f r t is group of patients.
In a previous study, we characterized the protein 
expr s ion of t  tissue inhibitor of metalloproteinases-1 
(TIMP-1) in astrocytic brain tumors and found that the 
Abstract Tissue inhibitor of metalloproteinases-1 (TIMP-
1) has been associated with poor prognosis and es stance 
towards chemotherapy in several cancer f rms. In a previ-
ous study we found an association bet en a low TIMP-1 
tumor immunoreactivity and increased survival for glio-
blastoma patients, when compared to moderate and high 
TIMP-1 tumor immunoreactivity. The aim of the resent 
study was to further evaluate TIMP-1 as a biomarker n gli-
omas by studying TIMP-1 gene copy numbers by fluores-
cence in situ hybridization (FISH) on 33 glioblastoma biop-
sies and by measuring levels of TIMP-1 in p asma obtained 
pre-operatively from 43 patient  (31 gliomas including 21 
glioblastomas) by enzyme-linked immunosorbent assay 
(ELISA). The results showed TIMP-1 gene copy numbers 
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Denmark between September 2009 and February 2010. All 
patients included had primary lesions not previously treated 
except the patient with a recurrent anaplastic oligoastrocy-
toma. Informed consent was obtained from patients before-
hand and blood samples were collected at the initial visit 
prior to surgery. Control blood samples were collected from 
healthy donors after informed consent. Fresh tumor tissue 
biopsies from all tumor patients were fixed in 4 % neutral 
buffered formalin and paraffin embedded. Three µm sec-
tions were stained with haematoxylin eosin to define rep-
resentative tumour regions. All samples were classified 
according to WHO guidelines 2007 [1].
Cohort II
Two tissue micro arrays (TMAs), consisting of 9 and 24 
glioblastoma biopsies, respectively, were produced from 
archival material at the Department of Pathology, Odense 
University Hospital, Denmark, between 2004 and 2008.
The present study was approved by The Regional Sci-
entific Ethical Committee (Approval Number S-20080086).
FISH analysis
FISH analysis was performed on the two TMAs described 
above, in order to elucidate TIMP-1gen  copy number. The 
TIMP-1 probe mixture was developed by Dako A/S. A sche-
matic illustration of the TIMP-1/CEN-X pr be mix localization 
on chromosome X is illustrated in Fig. 1. FISH wa  performed 
according to Dako Histology FISH Accessory Kit (K5599). 
In brief, paraffin sections were deparaffinized and rehydrated. 
Sections were placed in pre-treatment buffer and pre-treatment 
was performed using a microwave oven. Subsequently, the sec-
tions were incubated with RTU-pepsin for 2 min a  37 °C and 
washed twice for 3 m n. Slides were air-dried for 15–20 min, 
followed by application of 10 µl probe mix. Hybridization was 
carried out for approximately 20 h using a elting temperature 
protein expression increas d with umor grade (World 
Health Organisation (WHO) grade II–IV). Moreover we
found that glioblastoma patients with a low TIMP-1 expres-
sion had a significant longer overall survival than patients 
with a moderate or high TIMP-1 protein expre sion [3]. In 
line with our report, high TIMP-1 pr tein xpression levels 
in tumor tissue or in plasma ob ained p e-operat vely have 
been associated with poor progn sis in breast and colorectal 
cancer amongst others [4–12].
Immunohistochemistry can be difficult to quantify and 
can be dependent on pre-analy cal factor  such a  hypoxia, 
time and type of fixation as well as analytical variables such 
as choice of antibody and type of antigen retrieval method. 
In addition to this, gliomas can be difficult to reach surgi-
cally and are known for being highly necrotic. The necrosis 
may comprise up to 80 % of the tumor area and is a diag-
nostic hallmark in glioblastoma [1]. Therefore, vital tumor 
tissue is often sparse in contrast to blood sampl s, which 
are easier to obtain. In this study, we aimed to d termine (1) 
whether assessments of TIMP-1 g e c py number in the 
tumor cells and/or (2) measurement f plasm  TIMP-1 pro-
tein levels could substitute TIMP-1 immunohistochemistry 
in glioma research.
In order to investigate the TIMP-1 gene copy number, we 
produced a new TIMP-1 probe suitable for fluorescence in 
situ hybridization (FISH) and estimated theTIMP-1/Cen-
tromere region on chromosome X (CEN-X) ratio in 33 glio-
blastoma biopsies. The ratios were correlated to the TIMP-1 
immunoreactivity in the same biopsies. In add tion, blo d 
samples and biopsies were collected from 43 brain tumor 
patients, comprising 20 glioblastoma patie ts, and the 
TIMP-1 plasma levels were correlated to TIMP-1 immuno-
reactivity in the matched biopsies.
The results showed neither amplification nor loss of the 
TIMP-1 gene. The TIMP-1 levels me ured in plasma were 
not significantly higher than the TIMP-1 levels measured in 
healthy matched controls. No significant correlations were 
identified between the immunohistochemical tumor cell 
TIMP-1 levels and the FISH results or the plasma TIMP-1 
levels. The study thus suggests that TIMP-1 immunohisto-
chemistry is the method of choice when studying TIMP-1 as 
a biomarker in glioblastomas.
Materials and methods
Patients included in the study
Cohort I
Blood samples and corresponding tumor tissue biopsies 
were collected from 43 patients who underwent initial 
surgery of a brain tumor at Odense University Hospital, 
Fig. 1 Schematic illustration of the TIMP-1/CEN-X probe mix local-
ization on chromosome X. The TIMP-1 targeting part of the probe con-
sisted of Texas Red labeled BAC clone RP11-466C12. The BAC clone 
covers the entire TIMP-1 genom c sequence and flanking regions. 
Start and end pos. according to UCSC Genome Browser Feb. 2009: 
47392808–47588710. The chromosome X centromere targeting part of 
the probe consisted of a mixture of three FITC labeled Peptide Nucleic 
Acid oligos specific for the CEN-X α-satellite region
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positive cells, score 1 to 2 % to <15 % positive cells, score 2 
to 15% to <40  % positive cells and score 3 to 40 % to 100 % 
positive cells. Regarding the tumor cell staining intensity, 
the score 0 corresponds to no staining, score 1 to faint stain-
ing, score 2 to moderate staining and score 3 to intense 
immunostaining. The percentage of positive tumor blood 
vessels and the blood vessel staining intensity were assessed 
in the same way in the biopsies, resulting in a total score 
between 0 and 12 for each biopsy. For comparison with the 
tumor cell TIMP-1 gene copy numbers and TIMP-1/CEN-X 
ratios, the TIMP-1 immunoreactivity in the TMAs was only 
assessed in the tumor cells.
Statistics
Estimation of Spearman’s rank correlation coefficient was 
performed between TIMP-1/CEN-X ratios and immunohis-
tochemistry (IHC) scores as well as between plasma val-
ues and IHC scores using Graph Pad Prism 5.0 (Graphpad 
Software). For each patient the plasma TIMP-1 was com-
pared to plasma TIMP-1 measured in two healthy subjects 
using a linear model with the TIMP-1 log transformed and 
adjusted for gender and age. The healthy subject samples 
are described in Nielsen et al. [7] and the analysis was 
performed using SAS (SAS v9.1, SAS Institute). The 
reporting recommendations for tumor marker prognostic 
studies (REMARK) guidelines [15] w re followed wher-
ever applicable.
Results
TIMP-1 gene copy number and TIMP-1 
immunoreactivity in glioblastoma
In cohort II, the TIMP-1 gen , localized on chromosome X, 
was in general detected in one or two copies per nucleus 
depending on the gender of the patient. The ratio of TIMP-1 
genes (Fig. 2a, red signal) compared to the centromere sig-
nals (Fig.2a, green signal) per nucleus was in general close 
to 1, but varied between 0.7 and 1.09, suggesting neither 
amplification nor loss of the TIMP-1 gene (Table1).
TIMP-1 immunohistochemistry, performed on adja-
cent paraffin sections from patients belonging to cohort II, 
revealed a high degree of variation of the TIMP-1 protein 
expression (Fig. 2b–d; Table 1). In glioblastomas with a 
TIMP-1/CEN-X ratio of approximately 1, biopsies with a 
low TIMP-1 expression (Fig. 2b) as well as biopsies with 
a high TIMP-1 expression (Fig. 2d) were observed. A high 
TIMP-1 protein expression was found in the biopsy from 
patient 4 (Fig. 2c), whereas the TIMP-1 FISH analysis 
showed a low TIMP-1/CEN-X ratio of 0.7 (Table 1) in this 
biopsy. The TIMP-1 immunoreactivity in the tumor cells 
of 82°C and a hybridization temperature of 45 °C. Coverslips 
were mounted using fluorescence mounting medium with 
DAPI counter staining of the cell nuclei. Detailed information 
on development of TIMP-1 probe mixtu and FISH analysis 
is given in Online Resource 1.
Assessment of TIMP-1 copy numbers and TIMP-1/
CEN-X ratios
Hybridization signals in the tumor cells in sections obtained 
from cohort II were scored using a Leica D 6000 micro-
scope (Leica) equipped with a 100× oil-immersion objec-
tive (numeric aperture, 0.17). A dual-bandpass fluorescence 
filter (Leica) was used to visualize the fluorescein isothio-
cyanate (FITC) and Texas Red signals simultaneously. Sixty 
non-overlapping interphase nuclei with int ct morphology, 
based on 4′,6-diamidino-2-phenylindole (DAPI) counter-
staining, were scored to de ermine he number of hybridiza-
tion signals for each TIMP-1gene (red color) and CEN-X 
(green color) and the TIMP-1/CEN-X ratio was estimated.
Collection of blood samples and pl sma TIMP-1 
measurements
From cohort I, venous blood samples were collected in 
EDTA coated tubes (Becton-Dickens n) at th  Department 
of Neurosurgery, Odense University Hospital, Denmark 
and placed on ice immediately. Within 1h the plasma w s 
separated from blood cells by centrifugation at 2500 RPM 
for 25 min. Subsequently, plasma was stored at −80 °C. A 
well-established sensitive and specific sandwich ELISA was 
used for measuring the total amount (complexed and non-
complexed) TIMP-1 protein level in the lasma samples 
as described previously [13]. Blood samples from h l hy 
donors were collected and processed in the same way.
TIMP-1 immunohistochemistry
The TIMP-1 immunoreactivity was assessed o  paraf-
fin sections from both cohort I and cohort II. For cohort II 
formalin fixed paraffin embedded tissue (FFPE) TMA sec-
tions adjacent to the sections used or TIMP-1 FISH were 
stained. In cohort I, TIMP-1 immunoreactivity was studied 
in whole mount sections from FFPE tis ue. Th  TIMP-1 
immunohistochemistry was perform usin  th  monoclo-
nal VT7 antibody [14] as described earlier [3]. Ass ssment
of the immunohistochemical TI P-1 expressi n was based 
on a semiquantitative microscopy based coring system 
used previously [3] evaluating the avera e percentag  of 
TIMP-1 positive tumor cells and blo d vessels and their
average staining intensities, whereas necrotic reas and 
invasion zones were excluded. Regarding the percentage of
positive tumor cells, the score 0 corresponds to 0 % o <2 % 
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In addition, corresponding tumor biopsies were immu-
nohistochemically stained for TIMP-1 and scored (Table 2; 
Fig. 3). The staining was performed on full slides and the 
scores given represented mean total scores for the whole 
vital tumor area. Six biopsies were excluded due to lack of 
viable tumor tissue, leaving 37 of the 43 for analysis. In gen-
eral, no association was seen between TIMP-1 plasma lev-
els and total TIMP-1 immunohistochemical scores (Fig. 3e). 
Furthermore no association was seen between TIMP-1 in 
plasma and TIMP-1 tumor cell score or TIMP-1 vessel 
score (data not shown). A high plasma level was not neces-
sarily associated with a high TIMP-1 immunoreactivity in 
the biopsy (Fig. 3a) and high TIMP-1 immunoreactivity was 
detected in many glioblastoma biopsies (Fig. 3b) with nor-
mal plasma TIMP-1 (Table 2). The lowest plasma level was 
measured in patient 27 (Fig. 3c, d), but n the corresponding 
biopsy, areas with both high TIMP-1 tumor cell immunore-
activity (Fig. 3c) as well as areas with low TIMP-1 tumor 
cell immunoreactivity but presence of TIMP-1 positive 
tumor blood vessels (Fig. 3d) were detected illustrating the 
heterogenic nature of the TIMP-1 staining.
Discussion
In the present study we performed TIMP-1 FISH analysis 
on 33 glioblastomas (cohort II) to elucidate the frequency 
of TIMP-1 gene aberrations. Furthermore, we measured 
TIMP-1 plasma levels in 43 brain tumor patients including 
was scored, resulting in a tot l score betwe n 0 and 6 for 
each biopsy.
We did not find any significant correlation between 
TIMP-1 gene copy number and TIMP-1 immunoreactiv-
ity for females (Pearson r = 0.16), male  (Pearson r = 0.25) 
or for all the patients combined, when taking th  expected 
number of chromosome X into account (Pearson r = 0.27). 
Moreover, no correlations between the TIMP-1/CEN-X 
ratio and the total immunohistochemical scores (Pearson 
r = 0.13) were found.
TIMP-1 in blood samples versus TIMP-1 reactivity in 
biopsies
The 43 brain tumor patients constituting coh rt I are 
described in Table 2 and included 29 glioma pat ents of 
whom 20 were glioblastoma patients. The median value 
of plasma TIMP-1 in the 43 samples was 78.3ng/ml 
(range 58.8–131.9 ng/ml) compared to a median value 
for healthy subjects of 74.8 ng/ml (range 65.0–84.3 ng/
ml) (Table 2). For the glioblastomas, the median plasma 
TIMP-1 was 80.1 ng/ml (range 59.5–131.9 ng/ml) and 
76.4 ng/ml (range 70.0–84.3 ng/ml) for the matched 
healthy subjects. Thus, no significant differences were 
seen between plasma TIMP-1 levels measured in brain 
tumor patients compared to healthy ubjects. However, 
a slightly elevated TIMP-1 level was detected in a few 
patients (patient 7, 21 and 23 in Table 2), but no bvious 
pattern was recognized.
Fig. 2 The ratio between TIMP-1 gen s (a, redsignal) and CEN-X 
(a, green signal) was assessed using FISH in 33 glioblastoma biop-
sies. TIMP-1 immunohistochemistry was performed on adjacent 
paraffin sections (b–d) revealing a higher degree of variation of the 
TIMP-1 immunoreactivity. In glioblastomas with a FISH score of 
approximately 1, biopsies with a low TIMP-1 expression (b) as well 
as b opsies with a high TIMP-1 expression (d) were obs rved. A high 
TIMP-1 protein expression was found in the biopsy from patient 4 
(c), whereas the TIMP-1 FISH analysis showed a low TIMP-1/CEN-X 
r ti  of 0.7 (Table 1)  Scale bar 100 µm
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by FISH analysis [16 , 17 ], whereas amplification of the 
human epidermal growth factor receptor 2 (HER2) oncogene 
has predictive value in breast cancer [18–20 ]. By perform-
ing TIMP-1 FISH we aimed to elucidate (1) if the TIMP-1 
gene was deleted or amplified in glioblastomas and (2) if the 
increased TIMP-1 immunoreactivity found in glioblastomas 
could be associated with TIMP-1 gene amplification.
In general, the TIMP-1/CEN-X ratio was close to 1, but 
varied between 0.7 and 1.09, however, we did not have pre-
defined cut-off values for TIMP-1 amplification or deletion, 
20 glioblastoma patients (cohort I). TIMP-1/CEN-X rati s 
and plasma levels were then compared to the immunohis-
chemical TIMP-1 expression in the corresponding biopsies.
FISH analysis is a powerful method for plementing
biomarkers in the clinic. It is asy to perform on he paraf-
fin embedded tumor biopsies being available in pathology 
departments. The FISH method al ows as essment of spe-
cific gene aberrations and the FISH signals are relatively 
easy to quantify. For example, co-d letion of 1p19q has 
prognostic value in oligodendroglial tumors when assessed 
Table 1 TIMP-1 FISH analysis and TIMP-1 immunohistochemistry performed on TMAs consisting of 33 glioblastoma biopsies




1 M 71 71 1.00 3
2 M 76 78 0.97 4
3 F 201 185 1.09 4
4 F 96 137 0.70 5
5 M 60 60 1.00 2
6 M 112 108 1.04 2
7 M 65 65 1.00 2
8 F 109 108 1.01 2
9 M 61 62 0.98 3
10 F 110 110 1.00 5
11 M 60 60 1.00 6
12 F 173 167 1.04 3
13 M 64 61 1.05 6
14 M 61 60 1.02 3
15 M 75 73 1.03 4
16 M 122 114 1.07 4
17 M 70 68 1.03 3
18 F 115 116 0.99 4
19 F 104 103 1.01 3
20 M 68 68 1.00 5
21 F 108 103 1.05 4
22 M 60 60 1.00 3
23 M 139 139 1.00 3
24 F 134 137 0.98 2
25 M 60 60 1.00 4
26 M 122 120 1.02 0
27 M 61 61 1.00 0
28 M 80 77 1.04 2
29 M 60 60 1.00 5
30 M 65 66 0.98 2
31 F 121 121 1.00 3
32 M 74 79 0.94 3
33 F 99 97 1.02 4
The TIMP-1 signals and CEN-X signals were counted in 60 cells per biopsy and the TIMP-1/CEN-X ratio wa calculated. The TIMP-1 immu-
nostaining was scored according to TIMP-1 positive tumor cells (0–3) and tumor cell staining intensity (0–3) resulting in a total IHC score 
between 0 and 6.
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Patient no.Gender male/
female






1 M 64 GBM 88.8 75.9 109.4 7
2 M 38 R-AOA 71.0 65.0 93.7 6
3 M 56 GBM 71.2 72.4 104.3 9
4 F 65 DA 62.8 73.4 105.7 8
5 M 77 M-PAC 75.5 82.1 118.2 6
6 M 65 SS 74.5 76.4 110.1 3
7 F 64 GBM 107.4 73.0 105.1 Na
8 F 62 GBM 64.6 72.1 103.9 8
9 F 58 DA 58.9 70.4 101.4 Na
10 F 56 GBM 60.3 70.0 100.2 6
11 M 61 GBM 63.6 74.6 107.5 6
12 M 72 GBM 59.5 79.6 114.7 6
13 F 70 AOD 70.7 75.6 108.9 3
14 M 53 NM 66.9 71.1 102.4 Na
15 M 75 M-LAC 65.6 81.1 116.8 7
16 M 72 GBM 73.4 79.6 114.7 10
17 F 66 M-BAC 69.4 73.8 106.4 5
18 F 72 GBM 61.8 76.5 110.2 6
19 M 46 DA 68.2 68.2 98.3 4
20 M 66 GBM 97.7 76.8 110.7 7
21 M 67 GBM 131.9 77.3 111.4 7
22 M 52 M-MM 80.3 70.7 101.8 4
23 F 67 LF 127.2 74.3 107.0 Na
24 M 40 AA 53.9 65.8 94.8 6
25 F 77 GBM 99.3 78.8 113.6 7
26 F 68 AOA 80.8 74.7 107.5 3
27 M 68 GBM 65.3 77.8 112.0 8
28 M 59 GBM 81.4 73.7 106.2 9
29 M 62 GBM 71.0 75.0 108.1 6
30 M 64 M-LAC 76.6 75.9 109.4 7
31 F 55 AA 66.1 69.1 99.6 8
32 M 68 GBM 75.4 77.8 112.0 3
33 M 70 AA 88.4 75.6 108.9 8
34 M 81 GBM 82.8 84.0 121.1 11
35 M 82 GBM 87.8 84.3 121.8 7
36 M 79 M-LAC 116.1 83.0 119.6 5
37 M 60 GBM 76.6 74.1 106.8 11
38 M 74 AA 78.2 80.6 116.1 Na
39 F 69 LF 81.8 75.2 108.3 8
40 M 46 AF 89.1 68.2 98.3 5
41 F 66 GBM 81.5 73.8 106.4 9
Table 2 Blood samples were collected from 43 brain tumor patients including 20 glioblastoma patients
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of glioblastoma patients were characterized using a protein 
array [30]. The authors found increased serum levels of 
TIMP-1 when comparing 36 glioblastoma samples to five 
control patients, hospitalized for elective spinal surgery, 
with no consideration of age and gender. A possible expla-
nation for the different results may be the different methods 
and materials used in the studies and especially the control 
group used for comparison. In the present study, we com-
pared each glioblastoma sample to two healthy subjects 
matched by gender and age, since studies have suggested 
especially age and gender to significantly affect plasma 
TIMP-1 levels [7, 13].
We detected a median plasma TIMP-1 level of 80.1 ng/
ml (range 59.5–131.9 ng/ml) in the glioblastoma patients. 
The median TIMP-1 level as well as the narrow range is 
rather low when compared to studies describing plasma 
TIMP-1 levels in breast and colorectal cancer using the same 
method and laboratory. In a recent study, 4509 individuals, 
examined for colorectal cancer, had a median TIMP-1 level 
of 88.4 ng/ml (range 27.4–1166.0 ng/ml) [7]. Out of the 
4509 individuals, 294 of the patients were diagnosed with 
colorectal cancer. The median level in the colorectal cancer 
patients increased from 98.5 ng/ml in stage I to 137.3 ng/
ml in stage IV, with a significantly higher median TIMP-1 
level found in stage IV patients compared to stage I–III. 
When TIMP-1 plasma levels were measured in breast can-
cer patients [37] a plasma median level of 81.5 ng/ml (range 
41.9–174.9 ng/ml) was found. However, when measuring 
the median TIMP-1 in 46 patients with advanced disease 
in the same study, a significantly higher TIMP-1 level of 
108.7 ng/ml (59.7–560.7 ng/ml) was detected [37]. Even for 
the highly malignant glioblastomas in the present study, we 
did not detect significantly higher levels (59.5–131.9 ng/ml) 
when compared to controls (65.0–84.3 ng/ml). The blood 
brain barrier may play a role in the lack of increased TIMP-1 
protein in blood samples from glioblastoma patients. In the 
present study, however, we had access to the pre-operative 
MRI scans for the patients included. All glioblastomas 
since, to our knowledge, TIMP-1 FISH analysis in-
tomas or other cancers has not been described before. In 
general, cut-off definitions have been discussed for 1p/19q 
co-deletions as well as for HER2 amplification. For the 
1p/19q co-deletions, ratios rangi g from 0.15 to 0.7 have 
been used as definition for deletions [21 –23], whereas a rati  
less than 0.5 was suggested i  the guidelines writ en by the 
SIOP Europe Neuroblastoma Pathol gy, Biology and Bone 
Marrow Group [24]. Regarding HER2 amplification, a ratio 
ranging between 1.8 and 2.2 has been considered as gene
amplification although a ratio of 1.5 has been suggested as 
a more biological founded value [25, 26]. Based on th s  
studies, it is suggested that th  TIMP-1/CEN-X ratios found
in the present study were within a nor al range. In con-
trast to the rather constant FISH ratio, we detected a broader 
variation in the TIMP-1 immunoreactivities in the gliobla-
tomas. However, we did not find any association between 
the TIMP-1 protein expression and TIMP-1/CEN-X ratios. 
Based on these results, elevated TIMP-1 immun activity 
in glioblastomas should be explained by other mechanisms 
than gene amplification.
In several TIMP-1 biomarker studies, the TIMP-1 pro-
tein levels have been measured in pre-operative blood 
samples and it has been demo trated th plasma TIMP-1 
in breast and colorectal cancer are significantly associated 
with tumor grade as well as patient surviva  [6, 8, 27 –36]. 
Since gliomas can be difficult to reach surgically and vital 
tumor tissue is often sparse a blood sample is much asier 
to obtain. We investigated w th r plasma TIMP-1 pro ei  
levels collected prior to surg ry corre at d with TIMP-1 
tumor immunoreactivity. The ELISA used in the pres-
ent study is a well-established and thoroughly validated 
assay [13]. The ELISA measures the total leve s of TIMP-1 
including both uncomplexed and lexed TIMP-1. The 
TIMP-1 levels detected in plasma from the brain tumor 
patients did not differ significantly when compared to the 
TIMP-1 levels in healthy subject  matche  by ag  and g n-
der. However, in another study, serum angiogenic profiles 
Patient no.Gender male/
female






42 F 50 M-LAC 68.7 67.1 96.7 Na
43 M 52 M-LAC 74.2 70.7 101.8 0
Plasma TIMP-1 was measured and compared to two healthy controls matched by age and gender. Only two glioblastoma patients and one 
lymphoma patient were slightly above the upper 95 percentile (Patient 7, 21 and 23). TIMP-1 immunohistochemistry was performed on the cor-
responding biopsies from 37 of the patients. The TIMP-1 expression was scored according to TIMP-1 positive tumor cells (0–3), tumor blood 
vessels (0–3) as well as the staining intensities (0–3) resulting in a total score between 0 and 12
The diagnoses were: DA diffuse astrocytoma, AA anaplastic astrocytoma, AOD anaplastic oligoastrocytoma, AOD anaplastic oligodendro-
glioma, GBM glioblastoma, R-AOA recurrent anaplastic oligoastrocytoma, AE anap astic ependynoma, SS synovial sarcoma, LFlymphoma, 
M-LAC metastasis from lung adenocarcinoma, M-MM metastasis from malignant melanoma, M-PAC metastasis from prostate adenocarci-
noma, M-BAC metastasis from breast adenocarcinoma, NA not available
Table 2 (continued) 
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reach the blood directly. In line with this, we were not able 
to find a clear correlation between TIMP-1 protein measured 
in pre-operative blood samples and TIMP-1 protein levels 
in the corresponding biopsies. This is in accordance with a 
previous study [37] where comparison of plasma TIMP-1 
with TIMP-1 protein levels in tumor extracts from primary 
breast tumor patients, revealed a non-significant correlation.
The role of TIMP-1 as a biomarker has in recent years 
become increasingly interesting in relation to the second line 
treatment of glioblastomas consisting of the vascular endo-
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toma, R-AOA recurre t anaplastic oligoastrocytoma, AE anap astic 
ependynoma, SS synovial sarcoma, LF lymphoma, M-LACmetas-
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me anoma, M-PAC metastasis from prostate adenocarcinoma, M-BAC 
me astasis from breast adenocarcinoma. Sc le bar 100 µm
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